Trovagene Investor Relations http://trovagene.investorroom.com/ Trovagene Investor Relations Trovagene Announces Activation of First Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075 http://trovagene.investorroom.com/2017-11-13-Trovagene-Announces-Activation-of-First-Clinical-Trial-Site-in-Phase-1b-2-Acute-Myeloid-Leukemia-AML-Trial-for-PCM-075 Activation of first trial site for Phase 1b/2 clinical trial of PCM-075, in combination with standard-of care, to evaluate dose and scheduling, and preliminary anti-leukemic activity Mon, 13 Nov 2017 05:00:00 -0800 http://trovagene.investorroom.com/2017-11-13-Trovagene-Announces-Activation-of-First-Clinical-Trial-Site-in-Phase-1b-2-Acute-Myeloid-Leukemia-AML-Trial-for-PCM-075 Trovagene Announces Third Quarter 2017 Company Highlights and Financial Results http://trovagene.investorroom.com/2017-11-09-Trovagene-Announces-Third-Quarter-2017-Company-Highlights-and-Financial-Results Thu, 09 Nov 2017 07:32:00 -0800 http://trovagene.investorroom.com/2017-11-09-Trovagene-Announces-Third-Quarter-2017-Company-Highlights-and-Financial-Results Trovagene's PLK1 Inhibitor (PCM-075) Demonstrates Synergy with Zytiga® (abiraterone acetate) in Castration Resistant Prostate Cancer Tumor Cells http://trovagene.investorroom.com/2017-10-18-Trovagenes-PLK1-Inhibitor-PCM-075-Demonstrates-Synergy-with-Zytiga-R-abiraterone-acetate-in-Castration-Resistant-Prostate-Cancer-Tumor-Cells PCM-075 enhances activity of abiraterone in mCRPC tumors cells and may represent a novel treatment option to extend the benefit of anti-androgen therapy Wed, 18 Oct 2017 05:00:00 -0700 http://trovagene.investorroom.com/2017-10-18-Trovagenes-PLK1-Inhibitor-PCM-075-Demonstrates-Synergy-with-Zytiga-R-abiraterone-acetate-in-Castration-Resistant-Prostate-Cancer-Tumor-Cells FDA Grants Orphan Drug Designation to Trovagene's PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia (AML) http://trovagene.investorroom.com/2017-10-09-FDA-Grants-Orphan-Drug-Designation-to-Trovagenes-PLK1-Inhibitor-PCM-075-for-the-Treatment-of-Acute-Myeloid-Leukemia-AML Mon, 09 Oct 2017 05:00:00 -0700 http://trovagene.investorroom.com/2017-10-09-FDA-Grants-Orphan-Drug-Designation-to-Trovagenes-PLK1-Inhibitor-PCM-075-for-the-Treatment-of-Acute-Myeloid-Leukemia-AML Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis http://trovagene.investorroom.com/2017-09-20-Trovagene-Strengthens-Board-of-Directors-with-Appointment-of-Oncology-Development-Veteran-Dr-Athena-Countouriotis Dr. Athena Countouriotis joins Trovagene's Board of Directors, bringing significant experience in oncology clinical development and orphan indications Wed, 20 Sep 2017 05:00:00 -0700 http://trovagene.investorroom.com/2017-09-20-Trovagene-Strengthens-Board-of-Directors-with-Appointment-of-Oncology-Development-Veteran-Dr-Athena-Countouriotis